Company Focus
Takeda
Latest Takeda News
Pharmaceutical
Japan’s largest drugmaker Takeda announced new Phase III data for zasocitinib, its investigational, next-generation, highly selective and potent oral TYK2 inhibitor, zasocitinib, including secondary endpoint data showing consistent, high rates of skin clearance in patients with plaque psoriasis, including in high-impact sites. 17 July 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing therapies aimed at achieving a functional cure for chronic hepatitis B virus (HBV) infection. Arbutus Biopharma combines antiviral drug development with proprietary lipid nanoparticle (LNP) delivery technology used in nucleic acid medicines.
Latest News & Features of interest to Takeda
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted Japanese pharma major Shionogi’s supplemental New Drug Application (sNDA) for Fetroja (cefiderocol) for the treatment of pediatric patients (at least 26 weeks of gestational age) with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain Gram-negative microorganisms. 20 July 2026
Pharmaceutical
US pharma major Bristol Myers Squibb is expanding its partnership with NVIDIA, with plans to deploy an NVIDIA DGX SuperPOD built on DGX Vera Rubin NVL72 systems to support AI-led drug discovery and development. 20 July 2026
Pharmaceutical
The Gates Medical Research Institute (Gates MRI) has reached a milestone agreement with the Serum Institute of India (SII) to manufacture M72/AS01E, a novel tuberculosis (TB) vaccine candidate. 20 July 2026
Pharmaceutical
This article has been developed and funded by Daiichi Sankyo Europe.
With more than 125 years of drug research and development in Japan, Daiichi Sankyo was an early pioneer in antibody-drug conjugates (ADCs), years before the field attracted major industry investment. Along the way, the company has experienced both landmark successes and instructive setbacks – lessons that are now shaping its approach to R&D. 20 July 2026
Biotechnology
South Korea’s Samsung Biologics today announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group, a Swiss global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs). 20 July 2026
Biotechnology
USA-based BlossomHill Therapeutics has become the sixth biotech to line up for a stock market debut in July, filing to go public as investor enthusiasm for new drug listings shows little sign of cooling. The San Diego oncology specialist has applied to list on the Nasdaq Global Select Market under the ticker BLSM. 20 July 2026
Pharmaceutical
Last week saw AstraZeneca sign an accord with China’s Dizal Pharmaceutical for rights to the latter’s lung cancer drug Zegfrovy. Biogen released new Phase II data its Alzheimer’s candidate diranersen that raised questions. Celcuity won US Food and Drug Administration (FDA) for its investigational breast cancer drug Revtorpyk and Merck & Co announced FDA approval for its oral PCK9 cholesterol drug Lipfendra. Eli Lilly revealed plans to acquire mental health biotech AtaiBeckley for an upfront $2.8 billion. 19 July 2026
Pharmaceutical
Australia’s CSL Limited subsidiary CSL Seqirus has started shipping influenza vaccines to health care providers in the USA, helping them get prepared for the upcoming flu season, to target the H3N2 subclade K strain that drove last season’s historic surge. 18 July 2026
Biotechnology
Canadian genetic medicines company enGene Therapeutics announced changes to its board of directors as it prepares for potential regulatory milestones and commercial readiness for its investigational gene therapy, detalimogene voraplasmid, if approved. 17 July 2026
Pharmaceutical
The US Food and Drug Administration’s (FDA) approval of Utebzi (tebipenem pivoxil) gives physicians the first oral carbapenem option for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral treatment options. 17 July 2026
Latest In Brief for Takeda
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze